サルコペニア:パイプラインレビュー2019下半期

【英語タイトル】Sarcopenia - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA9120328)・商品コード:GDATA9120328
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月
・ページ数:80
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬及び医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Sarcopenia – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia – Pipeline Review, H2 2019, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body’s ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Sarcopenia – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 12, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sarcopenia – Overview
Sarcopenia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sarcopenia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sarcopenia – Companies Involved in Therapeutics Development
Biophytis SA
Faraday Pharmaceuticals Inc
Helixmith Co Ltd
Immusoft Corp
Keren Therapeutics
MYOS RENS Technology Inc
Neurotune AG
PhaseBio Pharmaceuticals Inc
ST Pharm Co Ltd
Teijin Pharma Ltd
Sarcopenia – Drug Profiles
ARM-210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Muscle Wasting Disorders and Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit SARM1 for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Muscular Atrophy, Sarcopenia and Traumatic Nerve Injury – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-501 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-504 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-1023 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NNMT for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclooxygenase 2 for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium iodide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEISARM-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sarcopenia – Dormant Projects
Sarcopenia – Discontinued Products
Sarcopenia – Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Biophytis files protocol amendment to optimize the SARA-INT phase 2b clinical trial for sarcopenia
Oct 04, 2019: Biophytis opens 22nd clinical site in the SARA-INT phase 2b trial of Sarconeos (BIO101) for the treatment of sarcopenia
Feb 18, 2019: Biophytis announces three oral and one poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research
Dec 07, 2018: BIOPHYTIS announces one oral presentation and two poster presentations at the 11th international conference on cachexia, sarcopenia and muscle wasting
Nov 27, 2018: BIOPHYTIS to host Key Opinion Leader Meeting on the biology of Aging and its application in Neuromuscular Diseases
Sep 04, 2018: Biophytis provides enrollment update in its phase 2b SARA-OBS and SARA-INT studies of Sarconeos in sarcopenia
May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami
Dec 08, 2017: Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD)
Dec 04, 2017: Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
Oct 30, 2017: BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia
Sep 25, 2017: Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia
May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sarcopenia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Sarcopenia - Pipeline by Biophytis SA, H2 2019
Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, H2 2019
Sarcopenia - Pipeline by Helixmith Co Ltd, H2 2019
Sarcopenia - Pipeline by Immusoft Corp, H2 2019
Sarcopenia - Pipeline by Keren Therapeutics, H2 2019
Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2019
Sarcopenia - Pipeline by Neurotune AG, H2 2019
Sarcopenia - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019
Sarcopenia - Pipeline by ST Pharm Co Ltd, H2 2019
Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2019
Sarcopenia - Dormant Projects, H2 2019
Sarcopenia - Dormant Projects, H2 2019 (Contd..1), H2 2019
Sarcopenia - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Sarcopenia, H2 2019 9
Number of Products under Development by Companies, H2 2019 10
Number of Products under Development by Universities/Institutes, H2 2019 12
Number of Products by Targets, H2 2019 15
Number of Products by Stage and Targets, H2 2019 15
Number of Products by Mechanism of Actions, H2 2019 17
Number of Products by Stage and Mechanism of Actions, H2 2019 17
Number of Products by Routes of Administration, H2 2019 19
Number of Products by Stage and Routes of Administration, H2 2019 19
Number of Products by Molecule Types, H2 2019 21
Number of Products by Stage and Molecule Types, H2 2019 21

【掲載企業】

Biophytis SA
Faraday Pharmaceuticals Inc
Helixmith Co Ltd
Immusoft Corp
Keren Therapeutics
MYOS RENS Technology Inc
Neurotune AG
PhaseBio Pharmaceuticals Inc
ST Pharm Co Ltd
Teijin Pharma Ltd

★調査レポート[サルコペニア:パイプラインレビュー2019下半期] (コード:GDATA9120328)販売に関する免責事項を必ずご確認ください。
★調査レポート[サルコペニア:パイプラインレビュー2019下半期]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆